BREAST CANCER METASTATIC TRIPLE NEGATIVE Clinical Trials

12 clinical trials for BREAST CANCER METASTATIC TRIPLE NEGATIVE across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A PHASE III, MULTISITE, RANDOMIZED, DOUBLE-BLIND TRIAL OF BNT327 IN COMBINATION WITH CHEMOTHERAPY VERSUS PLACEBO WITH CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY RECURRENT INOPERABLE OR METASTATIC TNBC DETERMINED INELIGIBLE FOR PD(L)1 THERAPY BASED ON PD-L1 NEGATIVE DISEASE — RECRUITING · PHASE3
• A RANDOMIZED, OPEN-LABEL, PHASE 2/3 STUDY OF IZALONTAMAB BRENGITECAN (BMS-986507) VERSUS TREATMENT OF PHYSICIAN’S CHOICE IN PATIENTS WITH PREVIOUSLY UNTREATED, LOCALLY ADVANCED, RECURRENT INOPERABLE, OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC) OR ER-LOW, HER2-NEGATIVE BC WHO ARE INELIGIBLE FOR ANTI-PD1/PD-L1 TREATMENT — RECRUITING · PHASE2
• A PHASE III, OPEN-LABEL, RANDOMISED STUDY OF DATOPOTAMAB DERUXTECAN (DATODXD) IN COMBINATION WITH DURVALUMAB COMPARED WITH INVESTIGATOR'S CHOICE OF CHEMOTHERAPY (PACLITAXEL, NAB-PACLITAXEL OR GEMCITABINE + CARBOPLATIN) IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-L1 POSITIVE LOCALLY RECURRENT INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TROPIONBREAST05). — RECRUITING · PHASE3
• A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN AND PEMBROLIZUMAB VERSUS TREATMENT OF PHYSICIAN¿S CHOICE AND PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED, LOCALLY ADVANCED, INOPERABLE, OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER, WHOSE TUMORS EXPRESS PD-L1 — RECRUITING · PHASE3
• A PHASE 3, OPEN-LABEL, RANDOMISED STUDY OF DATOPOTAMAB DERUXTECAN (DATODXD) VERSUS INVESTIGATOR¿S CHOICE OF CHEMOTHERAPY IN PATIENTS WHO ARE NOT CANDIDATES FOR PD 1/PD L1 INHIBITOR THERAPY IN FIRST-LINE LOCALLY RECURRENT INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TROPION BREAST02) — RECRUITING · PHASE3
• AN OPEN-LABEL, RANDOMIZED, PHASE 2/3 STUDY OF OLAPARIB PLUS PEMBROLIZUMAB VERSUS CHEMOTHERAPY PLUS PEMBROLIZUMAB AFTER INDUCTION OF CLINICAL BENEFIT WITH FIRST-LINE CHEMOTHERAPY PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH LOCALLY RECURRENT INOPERABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER (TNBC) (KEYLYNK-009) — RECRUITING · PHASE2
• A RANDOMIZED PHASE III TRIAL OF ADJUVANT THERAPY COMPARING DOXORUBICIN PLUS CYCLOPHOSPHAMIDE FOLLOWED BY WEEKLY PACLITAXEL WITH OR WITHOUT CARBOPLATIN FOR NODE-POSITIVE OR HIGH-RISK NODE-NEGATIVE TRIPLE-NEGATIVE INVASIVE BREAST CANCER — RECRUITING · PHASE3
• A PHASE III DOUBLE-BLIND RANDOMISED STUDY ASSESSING THE EFFICACY AND SAFETY OF CAPIVASERTIB + PACLITAXEL VERSUS PLACEBO + PACLITAXEL AS FIRST-LINE TREATMENT FOR PATIENTS WITH HISTOLOGICALLY CONFIRMED, LOCALLY ADVANCED (INOPERABLE) OR METASTATIC TRIPLE NEGATIVE BREAST CANCER — COMPLETED · PHASE3
• A PHASE II, OPEN LABEL, RANDOMISED, MULTI-CENTRE STUDY TO ASSESS THE SAFETY AND EFFICACY OF AGENTS TARGETING DNA DAMAGE REPAIR IN COMBINATION WITH OLAPARIB VERSUS OLAPARIB MONOTHERAPY IN THE TREATMENT OF METASTATIC TRIPLE NEGATIVE BREAST CANCER PATIENTS STRATIFIED BY ALTERATIONS IN HOMOLOGOUS RECOMBINANT REPAIR (HRR)-RELATED GENES (INCLUDING BRCA1/2) (VIOLETTE) — COMPLETED · PHASE2
• AN INTERNATIONAL, MULTI-CENTER, OPEN-LABEL, RANDOMIZED, PHASE III TRIAL OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN CHOICE IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER WHO RECEIVED AT LEAST TWO PRIOR TREATMENTS — COMPLETED · PHASE3
• A PHASE 1/1B, OPEN-LABEL, MULTICENTER, REPEAT-DOSE, DOSE-SELECTION STUDY OF CPI-444 AS SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH SELECTED INCURABLE CANCERS — COMPLETED · PHASE1
• "A PHASE II CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) AS MONOTHERAPY FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)-(KEYNOTE-086)," — COMPLETED · PHASE2

Refine this search